The imposition of 50% tariff on India by US President Donald Trump may result in a 5-10% decline in the income of Indian pharmaceutical companies as about 40% of India's total drug exports go to the US market. This may also increase the difficulties of medicines in America. In the financial year 2025, about 40 percent of India's drug exports were made to the US.

US President Donald Trump may have announced a 50 percent tariff on India. However, its deep impact will be seen not only on India but also on America.

In fact, a report has claimed that if a 50 percent tariff is actually imposed on goods imported from India, then it will have the biggest impact on the income of Indian pharmaceutical companies. Not only this, problems may have to be seen regarding medicines in America too. Let us tell you what the report says?

Big claim made in SBI report

Recently, a report by the State Bank of India came out. This report claimed that the imposition of tariffs by the US will have a profound impact on the pharmaceutical trade. This is because about 40 percent of India's total pharmaceutical exports go to the US market.

Apart from this, the report states that if the US President imposes a 50 percent tariff on Indian drug exports, then the income of pharmaceutical companies may fall by 5 to 10 percent in the next financial year. Let us tell you that there are many such big companies in India, which get 40 to 50 percent of their total revenue from the American market.

What do the figures say?

According to reports, about 40 percent of India's drug exports were made to the US in the financial year 2025. At the same time, India's share in the total drug imports of America was 6 percent in the financial year 2024.

It is believed that the potential 50 percent tariff imposed by Trump on India will also reduce the competitiveness of Indian products in the world's largest drug market and put pressure on profit.

PC:Jagran